PE20110942A1 - Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos - Google Patents

Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos

Info

Publication number
PE20110942A1
PE20110942A1 PE2011001143A PE2011001143A PE20110942A1 PE 20110942 A1 PE20110942 A1 PE 20110942A1 PE 2011001143 A PE2011001143 A PE 2011001143A PE 2011001143 A PE2011001143 A PE 2011001143A PE 20110942 A1 PE20110942 A1 PE 20110942A1
Authority
PE
Peru
Prior art keywords
protozoo
variable surface
modified
vsp
procedures
Prior art date
Application number
PE2011001143A
Other languages
English (en)
Inventor
Hugo Daniel Lujan
Original Assignee
Consejo Nac Invest Cient Tec
Univ Catolica De Cordoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec, Univ Catolica De Cordoba filed Critical Consejo Nac Invest Cient Tec
Publication of PE20110942A1 publication Critical patent/PE20110942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/68—Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

REFERIDA A UN PROTOZOO PARASITO MODIFICADO QUE COMPRENDE LA EXPRESION SIMULTANEA EN SU SUPERFICIE DE MAS DE UNA PROTEINA VARIABLE DE SUPERFICIE Y LA EXPRESION REDUCIDA DE LAS ENZIMAS DICER, ARN POLIMERASA RNA DEPENDIENTE (RdRP) O AMBAS, DONDE EL PROTOZOOSE SELECCIONA DE GIARDIA, PLASMODIUM, BABESIA Y TRYPANOSOMA. TAMBIEN ESTA REFERIDA A UNA VACUNA QUE COMPRENDE DICHO PROTOZOO Y A UN PROCEDIMIENTO PARA PURIFICAR EL REPERTORIO TOTAL DE PROTEINAS DE SUPERFICIE VARIABLE DE PROTOZOOS
PE2011001143A 2008-12-02 2009-12-02 Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos PE20110942A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11905808P 2008-12-02 2008-12-02

Publications (1)

Publication Number Publication Date
PE20110942A1 true PE20110942A1 (es) 2011-12-30

Family

ID=42233679

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001143A PE20110942A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa multiples proteinas variables de superficie (vsp), composicion inmunogenica que lo comprende y procedimientos
PE2015000436A PE20150889A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2015000436A PE20150889A1 (es) 2008-12-02 2009-12-02 Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos

Country Status (18)

Country Link
US (1) US9463229B2 (es)
EP (1) EP2364156B1 (es)
JP (3) JP2012510286A (es)
CN (1) CN102281884B (es)
AR (1) AR074458A1 (es)
AU (1) AU2009323734B2 (es)
BR (1) BRPI0917075B1 (es)
CA (1) CA2745470C (es)
CL (2) CL2011001309A1 (es)
CO (1) CO6390115A2 (es)
CR (1) CR20110377A (es)
EC (1) ECSP11011171A (es)
ES (1) ES2667773T3 (es)
MX (2) MX351579B (es)
NZ (2) NZ604943A (es)
PE (2) PE20110942A1 (es)
PT (1) PT2364156T (es)
WO (1) WO2010064204A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
US6171820B1 (en) * 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
JP2000083677A (ja) * 1998-09-17 2000-03-28 Bayer Ltd ダニワクチン
GB0000474D0 (en) * 2000-01-10 2000-03-01 Inal Jameel M Receptor

Also Published As

Publication number Publication date
CA2745470C (en) 2018-09-25
ES2667773T3 (es) 2018-05-14
BRPI0917075B1 (pt) 2019-11-12
JP2018024700A (ja) 2018-02-15
EP2364156B1 (en) 2018-01-31
MX351579B (es) 2017-10-20
US20120093871A1 (en) 2012-04-19
JP2012510286A (ja) 2012-05-10
CN102281884A (zh) 2011-12-14
CN102281884B (zh) 2015-09-30
WO2010064204A2 (en) 2010-06-10
US9463229B2 (en) 2016-10-11
JP2016000045A (ja) 2016-01-07
CO6390115A2 (es) 2012-02-29
EP2364156A2 (en) 2011-09-14
NZ593106A (en) 2013-05-31
BRPI0917075A2 (pt) 2016-08-02
PE20150889A1 (es) 2015-06-07
NZ604943A (en) 2014-08-29
AR074458A1 (es) 2011-01-19
PT2364156T (pt) 2018-04-24
CL2018002834A1 (es) 2019-04-05
AU2009323734B2 (en) 2016-06-30
CR20110377A (es) 2011-10-20
ECSP11011171A (es) 2011-09-30
CA2745470A1 (en) 2010-06-10
JP6793621B2 (ja) 2020-12-02
MX2011005815A (es) 2011-09-30
CL2011001309A1 (es) 2012-03-16
WO2010064204A3 (en) 2010-12-02
AU2009323734A1 (en) 2010-06-10

Similar Documents

Publication Publication Date Title
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
ECSP12011685A (es) Inmunoconjugados dirigidos
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
CR10290A (es) Metodos para reducir la aglomeracion de proteina
DOP2013000185A (es) Compuestos antivirales
ECSP12012211A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
BR112012015721A2 (pt) modificação covalente de proteínas dirigida por ligante
CO6551721A2 (es) Moduladores de cinasa novedosos
CR10555A (es) Vacunas para malaria
NI201100025A (es) Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CL2009001195A1 (es) Adyuvante inmune que comprende un inhibidor de iap capaz de modular la actividad inmune; composicion farmaceutica y vacuna que lo comprenden; metodo para mejorar una respuesta inmune de un individuo; metodo para tratar un cancer en un individuo; metodo para tratar infeccion; metodo para tratar trastornos autoinmune.
BR112012014925A2 (pt) compostos promotores de replicação de células beta e métodos de uso dos mesmos
CO2018004323A2 (es) Una composición que comprende dihidrato de n4–(ciclopropilmetil)–6– [(3r)–3–(metilamino)pirrolidin–1–il]pirimidin–2,4–diamina tartrato
ECSP23025065A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
WO2013055418A3 (en) Cross-protective arenavirus vaccines and their method of use
WO2012145582A3 (en) Methods and compositions for the specific inhibitions of egfr by double-stranded rna

Legal Events

Date Code Title Description
FG Grant, registration